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ABSTRACT
Objective In the Netherlands, the Gonococcal resistance 
to Antimicrobials Surveillance (GrAS) programme is carried 
out at Centres for Sexual health (CSh), which provide 
care for sexual high- risk populations. however, half of 
gonorrhoea infections are diagnosed in general practice 
(Gp). We performed a pilot study to explore expanding 
GrAS to Gps using laboratory- based surveillance. 
Additionally, antimicrobial resistance patterns of Gp and 
CSh patients were compared.
Methods three laboratories from different regions were 
included, which all perform gonorrhoea diagnostics for 
Gps and used eSwab for patient sampling. Additional 
culturing for all Gp patients with gonorrhoea took place 
from February to July 2018. After positive pCr- nucleic 
acid amplification test, residual eSwab material was used 
for culture. In positive cultures, susceptibility testing was 
performed for azithromycin, ciprofloxacin, cefotaxime 
and ceftriaxone using etest.
Results During the study period, 484 samples were 
put in culture. 16.5% of cultures were positive (n=80). 
Antimicrobial resistance levels were low, with 2.6% 
resistance to azithromycin, 21.5% to ciprofloxacin and 
0.0% to cefotaxime and ceftriaxone. resistance levels 
in CSh GrAS data (first half of 2018) were 19.2% 
for azithromycin, 31.5% for ciprofloxacin, 1.9% for 
cefotaxime and 0.0% for ceftriaxone.
Conclusions Culture positivity rates for Gp patients 
were low, probably due to long transportation times 
and awaiting pCr test results before attempting culture. 
positivity rates might be improved by making changes in 
sampling and/or transportation methods, but that would 
require involvement of Gps and patients instead of keeping 
the surveillance lab based. resistance levels appeared to 
be lower at Gps than at the CSh, indicating that resistance 
might emerge first in more high- risk populations. It is 
important to consider all potentially relevant patient 
populations when establishing a gonococcal antimicrobial 
resistance surveillance programme. however, based on the 
findings from this study the current GrAS programme will 
not be extended to Gps.
InTROduCTIOn
Neisseria gonorrhoeae infection (gonorrhoea) 
is one of the most common STIs in the Nether-
lands. In the past, N. gonorrhoeae has shown to 
be extremely capable of developing antimicrobial 
resistance, threatening the availability of effective 
treatment.1 Resistance to the current first- line anti-
biotic ceftriaxone has not yet been reported in the 
Netherlands,2 but has been seen in other countries, 
including the UK.3
To monitor gonorrhoea antimicrobial resistance 
in the Netherlands, the Gonococcal Resistance to 
Antimicrobials Surveillance (GRAS) programme 
was established in 2006. GRAS is a sentinel surveil-
lance system including 18 out of 24 Centres for 
Sexual Health (CSH). However, more than half 
of gonorrhoea diagnoses in the Netherlands are 
carried out in general practice (GP) (in 2016: 
6092 CSH diagnoses vs approximately 9000 GP 
diagnoses).2 Thus, many patients are not included 
in GRAS. Currently, it is unknown to what extent 
antimicrobial resistance patterns among CSH visi-
tors are representative for patients who visit the GP 
for STI testing. Gaining insight in the gonococcal 
antimicrobial resistance among GP patients could 
therefore provide useful information and will allow 
for a more comprehensive understanding of the 
current antimicrobial resistance patterns of gonor-
rhoea in the Netherlands.
In GP, gonorrhoea diagnoses are based on PCR- 
nucleic acid amplification test (NAAT). STI testing 
guidelines for GPs are similar to those at the CSH, 
but it is known that, for example, extragenital 
testing is less often performed by GPs.4 Culture is 
also not routinely performed, but is necessary to 
determine antimicrobial susceptibility. Because it 
requires more effort from GPs and their patients 
to collect additional samples for culturing, we first 
wanted to explore implementation of a laboratory- 
based surveillance that requires no additional 
sample collection. Therefore, the primary goal of 
this pilot study was to explore the feasibility of a 
laboratory- based GP surveillance of gonococcal 
antimicrobial resistance. Additionally, we aim 
to describe antimicrobial resistance patterns of 
patients with gonorrhoea in GP, and compare these 
to patterns of CSH patients.
MeThOdS
Laboratories were eligible for inclusion in the pilot 
study if they performed gonorrhoea diagnostics for 
GPs, if they were equipped to perform culture and 
susceptibility testing for N. gonorrhoeae and if they 
used ESwab for collection and transportation of 
samples. ESwab is a collection and transport system 
that contains enough liquid sample suspension to 
perform multiple tests on one specimen. It is there-
fore possible to first perform PCR- NAAT diagnos-
tics, and if positive for gonorrhoea perform culture 
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Figure 1 Minimum inhibitory concentration (MIC) value distributions 
for (A) azithromycin, (B) ciprofloxacin, (C) cefotaxime and (D) 
ceftriaxone susceptibility of Neisseria gonorrhoeae from the Gonococcal 
Resistance to Antimicrobials Surveillance (GRAS) in general practice 
pilot study and from the GRAS programme at Dutch Centres for Sexual 
Health in the first half of 2018.
using the same material. Three large laboratories participated in 
this study: one from an urban region (STAR- SHL) in the south-
west of the Netherlands, and two from rural regions in the north 
of the Netherlands (Certe and Izore).
The three laboratories collected data from GP patients that 
tested positive for gonorrhoea from February to July 2018. 
After positive NAAT, ESwab material was used for culture. In 
case of a positive culture, antimicrobial susceptibility testing was 
performed using Etest for four antibiotics: azithromycin, ceftri-
axone, ciprofloxacin and cefotaxime. The laboratories Certe and 
Izore did not culture urine samples and samples with a cycle 
threshold value over 30 due to low chance of succeeding. All labs 
reported data from both culture positive and negative patients, 
including sex, age, anatomical location of sampling, result of 
culture and results from antimicrobial susceptibility testing 
(minimum inhibitory concentration (MIC) values).
Materials used for sample collection and culture differed 
between the laboratories. Swabs used were ESwab from Copan 
(Certe) and BD (Izore), and the Σ-Transwab (STAR- SHL), all 
containing liquid Amies medium. Plates used for culture were for 
Certe chocolate agar and chocolate agar+VCTA (Mediaprod-
ucts), for STAR- SHL Neisseria selective medium PLUS (Thermo 
Scientific), and for Izore Chocolate Agar (GC II Agar with IsoVi-
taleX) (BD), Neisseria Selective Medium PLUS (Thermo Scien-
tific) and Mueller Hinton Chocolate Agar (BD).
Descriptive analyses were used to calculate culture positivity 
rates and the percentage of antimicrobial resistance. Antimi-
crobial resistance was defined using MIC breakpoints from the 
European Committee on Antimicrobial Susceptibility Testing 
(azithromycin >0.5 mg/L, ciprofloxacin >0.06 mg/L and cefo-
taxime and ceftriaxone >0.125 mg/L).5 Univariate logistic 
regression analyses were used to assess differences in culture 
positivity rates by patient characteristics. Age was included in 
three categories (<25, 25–34, >34). Multivariate analyses were 
not possible due to low numbers. We compared the antimicro-
bial resistance patterns from GP patients with data from the 
regular GRAS surveillance at CSH from the first half of 2018 
using Fisher’s exact test.
ReSulTS
A total of 469 GP patients tested positive for gonorrhoea at 
the three laboratories between February and July 2018: 323 at 
STAR- SHL, 77 at Certe and 69 at Izore. Some patients had samples 
from multiple anatomical locations. Therefore, culture was 
performed on 484 samples, of which 80 (16.5%) were positive. 
All analyses were performed on sample level. Most samples were 
urogenital (n=395), followed by anal (n=42) and oral (n=29). 
Eighteen samples were of unknown anatomical location. Of the 
three laboratories, Izore had a significant lower culture positivity 
rate (8.2% positive; OR 0.40, 95% CI 0.17 to 0.98) compared 
with STAR- SHL (18.1%) and Certe (17.5%). The anatomical loca-
tion of the sample was also significantly associated with culture 
positivity. Compared with vaginal swabs (16.2% culture positive), 
anal swabs were less likely to result in a positive culture (2.4% 
positive; OR 0.13, 95% CI 0.02 to 0.95), as were oral swabs (0.0% 
positive). Cultures from urine samples showed a significantly 
higher chance of succeeding (25.7% positive; OR 1.80, 95% CI 
1.02 to 3.18). Age and sex were not significantly associated with 
culture positivity in univariate analyses. See also online supplemen-
tary table 1. The 16.5% culture positivity rate at the GPs was lower 
than the average 54.7% culture positivity rate at the CSH in the 
first half of 2018.
Antimicrobial susceptibility testing was performed for the 80 
positive cultures. Resistance levels were low, with 2.6% resistant 
to azithromycin, 21.5% to ciprofloxacin and 0.0% to cefotaxime 
and ceftriaxone. Resistance levels in CSH GRAS data (first half 
of 2018) were 19.2% for azithromycin, 31.5% for ciprofloxacin, 
1.9% for cefotaxime and 0.0% for ceftriaxone. This difference 
was statistically significant for azithromycin (p<0.001), but not 
for ciprofloxacin (p=0.078) and cefotaxime (p=0.392). The 
MIC distributions including 95% CI from the GP population 
and the CSH population are shown in figure 1.
dISCuSSIOn
This study piloted a laboratory- based antimicrobial resistance 
surveillance for GP patients, without GPs or patients being 
involved. Culture positivity rates were low, and antimicrobial 
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resistance rates were lower than the rates seen in the GRAS 
programme at CSH.
The main limitation of this study was the small sample size. As 
this was a pilot study, we only enrolled the surveillance in three 
regions. We did however include both urban and rural laborato-
ries, so the findings are expected to be representative for other 
regions in the Netherlands as well. Due to the low culture posi-
tivity rates, the amount of samples available for susceptibility 
testing was limited. Therefore, extensive statistical analyses 
could not be performed. Furthermore, due to the low culture 
positivity rate, the representativeness of the results of the suscep-
tibility testing should be interpreted with caution.
The low GP culture positivity rate could be explained by the fact 
that in the pilot study PCR testing results had to be available before 
samples were put in culture, and as bacterial viability in a transport 
medium decreases over time,6 this delay might have caused decreases 
in culture positivity rates. According to the CSH GRAS protocol, 
PCR test results do not have to be awaited, and samples are put 
immediately in culture when received at the laboratory. In addition, 
transportation times from GP to laboratory could have been longer 
than at the CSH because GP practices are often further away from 
the laboratory, and because GPs did not know the samples would be 
used for culturing and therefore put in no additional efforts to ensure 
the samples were sent to the laboratory as soon as possible. The time 
between sample collection at GP and culturing was unknown at the 
laboratories. Samples were in all three laboratories collected from 
the GPs once per day. Estimations of time between sample collection 
and sample testing varied from a few hours to more than a day.
Results from this study also showed that the anatomical loca-
tion of the sample was strongly associated with culture positivity. 
Anal and oral samples had a lower chance of resulting in positive 
culture, which has been seen before.7–9 The finding that urine 
samples had a higher chance of succeeding was unexpected, 
since two laboratories said not to culture urine samples due to 
low expected culture positivity. Despite the fact that this finding 
is only based on univariate analysis, it does indicate that urine 
could also be used for culturing.
Antimicrobial resistance rates were compared between the GP 
and CSH populations. For all antimicrobials, resistance levels were 
lower among GP patients. These findings were only statistically 
significant for azithromycin, which could be due to the small sample 
size, but it gives an indication that antimicrobial resistance might 
occur more often among CSH visitors. This could be explained by 
the fact that ‘core groups’ with high risk of STI are known contrib-
utors to dissemination of antimicrobial resistant gonorrhoea,10 and 
CSH provide care especially for groups at high risk for STI, while 
the GP population is generally at lower risk.
The main aim of this study was to explore the feasibility of a 
laboratory- based GP surveillance of gonococcal antimicrobial 
resistance. It was possible to perform surveillance without engaging 
GPs and/or their patients, but it resulted in low culture positivity 
rates. For a more comprehensive and complete surveillance system 
the culture positivity rates should be improved, which is likely only 
possible with the involvement of GPs and patients. It is, however, 
undesirable to burden GPs with antimicrobial surveillance, as GPs 
are already under time pressure, and are not expected to perform 
public health surveillance tasks. Furthermore, the low antimicro-
bial resistance rates among GP patients indicate that antimicro-
bial resistance is more prevalent among CSH visitors, which are 
already well covered by the existing national GRAS surveillance. 
This also makes the establishment of a GP antimicrobial surveil-
lance less urgent.
In conclusion, it is important to consider all potentially rele-
vant patient populations when establishing a gonococcal antimi-
crobial resistance surveillance programme. However, the current 
findings indicate that additional efforts are needed to establish 
antimicrobial surveillance in GP practice, while resistance rates 
are low. Based on the findings from this study the current GRAS 
programme in the Netherlands will therefore not be extended to 
the GP population.
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